Johnson PW
Johnson PW
Professor of Medical Oncology, University of Southampton
Verified email at
Cited by
Cited by
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
B Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ...
Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 1998
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ...
Annals of oncology 26, v116-v125, 2015
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma
P Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ...
New England Journal of Medicine 374 (25), 2419-2429, 2016
Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma
J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ...
New England Journal of Medicine 372 (17), 1598-1607, 2015
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg, SM Morgan, HTC Chan, BP Morgan, AV Filatov, ...
Blood, The Journal of the American Society of Hematology 101 (3), 1045-1052, 2003
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of …
D Cunningham, EA Hawkes, A Jack, W Qian, P Smith, P Mouncey, ...
The Lancet 381 (9880), 1817-1826, 2013
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma …
JM Foran, AZ Rohatiner, D Cunningham, RA Popescu, P Solal-Celigny, ...
Journal of Clinical Oncology 18 (2), 317-324, 2000
Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study
AK Clift, CAC Coupland, RH Keogh, K Diaz-Ordaz, E Williamson, ...
bmj 371, 2020
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the …
AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ...
The Lancet Haematology 3 (5), e217-e227, 2016
Clinical trials of antibody therapy
MJ Glennie, PWM Johnson
Immunology today 21 (8), 403-410, 2000
Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma
A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ...
Journal of Clinical Oncology 37 (15), 1285, 2019
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
Blood, The Journal of the American Society of Hematology 126 (6), 739-745, 2015
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.
PW Johnson, AZ Rohatiner, JS Whelan, CG Price, S Love, J Lim, ...
Journal of clinical oncology 13 (1), 140-147, 1995
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
SA Beers, RR French, HTC Chan, SH Lim, TC Jarrett, RM Vidal, ...
Blood, The Journal of the American Society of Hematology 115 (25), 5191-5201, 2010
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
SF Barrington, W Qian, EJ Somer, A Franceschetto, B Bagni, E Brun, ...
European journal of nuclear medicine and molecular imaging 37, 1824-1833, 2010
The mechanisms of action of rituximab in the elimination of tumor cells
P Johnson, M Glennie
Seminars in oncology 30 (1), 3-8, 2003
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
A Hagenbeek, O Gadeberg, P Johnson, L Møller Pedersen, J Walewski, ...
Blood, The Journal of the American Society of Hematology 111 (12), 5486-5495, 2008
Anti-CD20 monoclonal antibodies: historical and future perspectives
SH Lim, SA Beers, RR French, PWM Johnson, MJ Glennie, MS Cragg
haematologica 95 (1), 135, 2010
J Michels, PWM Johnson, G Packham
The international journal of biochemistry & cell biology 37 (2), 267-271, 2005
The system can't perform the operation now. Try again later.
Articles 1–20